These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

272 related articles for article (PubMed ID: 18549347)

  • 81. Monoamine oxidase B inhibitors versus other dopaminergic agents in early Parkinson's disease.
    Caslake R; Macleod A; Ives N; Stowe R; Counsell C
    Cochrane Database Syst Rev; 2009 Oct; (4):CD006661. PubMed ID: 19821381
    [TBL] [Abstract][Full Text] [Related]  

  • 82. Noninvasive options for 'wearing-off' in Parkinson's disease: a clinical consensus from a panel of UK Parkinson's disease specialists.
    Fackrell R; Carroll CB; Grosset DG; Mohamed B; Reddy P; Parry M; Chaudhuri KR; Foltynie T
    Neurodegener Dis Manag; 2018 Oct; 8(5):349-360. PubMed ID: 29975112
    [TBL] [Abstract][Full Text] [Related]  

  • 83. Effective treatment of restless legs syndrome by safinamide in Parkinson's disease patients.
    Liguori C; Mercuri NB; Stefani A; Pierantozzi M
    Sleep Med; 2018 Jan; 41():113-114. PubMed ID: 29268951
    [No Abstract]   [Full Text] [Related]  

  • 84. Recent developments in the pharmacological treatment of Parkinson's disease.
    Tuite P; Riss J
    Expert Opin Investig Drugs; 2003 Aug; 12(8):1335-52. PubMed ID: 12882620
    [TBL] [Abstract][Full Text] [Related]  

  • 85. Effectiveness and safety of safinamide in routine clinical practice in a Belgian Parkinson's disease population: an open-label, levodopa add-on study.
    ; Bergmans B; Bourgeois P; Cras P; Dethy S; De Klippel N; Franco G; Garraux G; Geens K; Jacquerye P; Jeanjean A; Supiot F; Van der Linden C; Krygier C
    Acta Neurol Belg; 2023 Jun; 123(3):939-947. PubMed ID: 36201116
    [TBL] [Abstract][Full Text] [Related]  

  • 86. Renin-angiotensin system as a potential target for new therapeutic approaches in Parkinson's disease.
    Perez-Lloret S; Otero-Losada M; Toblli JE; Capani F
    Expert Opin Investig Drugs; 2017 Oct; 26(10):1163-1173. PubMed ID: 28836869
    [TBL] [Abstract][Full Text] [Related]  

  • 87. Safinamide.
    Fariello RG
    Neurotherapeutics; 2007 Jan; 4(1):110-6. PubMed ID: 17199024
    [TBL] [Abstract][Full Text] [Related]  

  • 88. 1-[2-(4-Benzyloxyphenoxy)Ethyl]Imidazole inhibits monoamine oxidase B and protects against neuronal loss and behavioral impairment in rodent models of Parkinson's disease.
    Chung JY; Lee JW; Ryu CH; Min HK; Yoon YJ; Lim MJ; Park CH
    J Neurosci Res; 2015 Aug; 93(8):1267-78. PubMed ID: 25711470
    [TBL] [Abstract][Full Text] [Related]  

  • 89. Green Spectrophotometric Platforms for Resolving Overlapped Spectral Signals of Recently Approved Antiparkinsonian Drug (Safinamide) in the Presence of Its Synthetic Precursor (4-Hydroxybenzaldehyde): Applying Ecological Appraisal and Comparative Statistical Studies.
    El-Sayed HM; El-Abassy OM; Abdellatef HE; Hendawy HAM; Ibrahim H
    J AOAC Int; 2022 Dec; 106(1):26-33. PubMed ID: 36214622
    [TBL] [Abstract][Full Text] [Related]  

  • 90. Neuroprotective and neuro-survival properties of safinamide against methamphetamine-induced neurodegeneration: Hypothetic possible role of BDNF/TrkB/PGC-1α signaling pathway and mitochondrial uncoupling protein -2(UCP-2).
    Sepehr A; Taheri F; Heidarian S; Motaghinejad M; Safari S
    Med Hypotheses; 2020 Oct; 143():110094. PubMed ID: 32682215
    [TBL] [Abstract][Full Text] [Related]  

  • 91. Hypersexuality Possibly Associated With Safinamide.
    Jiménez-Jiménez FJ; Alonso-Navarro H; Valle-Arcos D
    J Clin Psychopharmacol; 2017 Oct; 37(5):635-636. PubMed ID: 28796020
    [No Abstract]   [Full Text] [Related]  

  • 92. The effect of safinamide, a novel drug for Parkinson's disease, on pressor response to oral tyramine: a randomized, double-blind, clinical trial.
    Marquet A; Kupas K; Johne A; Astruc B; Patat A; Krösser S; Kovar A
    Clin Pharmacol Ther; 2012 Oct; 92(4):450-7. PubMed ID: 22948897
    [TBL] [Abstract][Full Text] [Related]  

  • 93. Safinamide mesylate, Brodalumab, Guselkumab, and Abaloparatide.
    Hussar DA; Kotova M
    J Am Pharm Assoc (2003); 2018; 58(1):123-127. PubMed ID: 29290341
    [No Abstract]   [Full Text] [Related]  

  • 94. Safinamide protects against amyloid β (Aβ)-induced oxidative stress and cellular senescence in M17 neuronal cells.
    Gu X; Zhang G; Qin Z; Yin M; Chen W; Zhang Y; Liu X
    Bioengineered; 2022 Jan; 13(1):1921-1930. PubMed ID: 35001806
    [TBL] [Abstract][Full Text] [Related]  

  • 95. Initial treatment of Parkinson's disease in 2016: The 2000 consensus conference revisited.
    Laurencin C; Danaila T; Broussolle E; Thobois S
    Rev Neurol (Paris); 2016; 172(8-9):512-523. PubMed ID: 27476416
    [TBL] [Abstract][Full Text] [Related]  

  • 96. Clinical pharmacokinetic and pharmacodynamic properties of drugs used in the treatment of Parkinson's disease.
    Deleu D; Northway MG; Hanssens Y
    Clin Pharmacokinet; 2002; 41(4):261-309. PubMed ID: 11978145
    [TBL] [Abstract][Full Text] [Related]  

  • 97. Pharmacokinetics of monoamine oxidase B inhibitors in Parkinson's disease: current status.
    Müller T; Möhr JD
    Expert Opin Drug Metab Toxicol; 2019 May; 15(5):429-435. PubMed ID: 31017021
    [TBL] [Abstract][Full Text] [Related]  

  • 98. Current and experimental treatments of Parkinson disease: A guide for neuroscientists.
    Oertel W; Schulz JB
    J Neurochem; 2016 Oct; 139 Suppl 1():325-337. PubMed ID: 27577098
    [TBL] [Abstract][Full Text] [Related]  

  • 99. Potential neuroprotection mechanisms in PD: focus on dopamine agonist pramipexole.
    Albrecht S; Buerger E
    Curr Med Res Opin; 2009 Dec; 25(12):2977-87. PubMed ID: 19842998
    [TBL] [Abstract][Full Text] [Related]  

  • 100. Pharmacological treatment of Parkinson disease: a review.
    Connolly BS; Lang AE
    JAMA; 2014 Apr 23-30; 311(16):1670-83. PubMed ID: 24756517
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.